Patients with schizophrenia smoke cigarettes at a higher rate than the general population. We hypothesized that a factor in this comorbidity is sensitivity to the reinforcing and reinforcement-enhancement effects of nicotine. Phencyclidine (PCP) was used to model behavioral changes resembling negative symptoms of schizophrenia in rats. Ultrasonic vocalizations (USVs) in rats have been used to measure emotional states, with 50 kHz USVs indicating positive states and 22 kHz USVs indicating negative states. Total and categorized numbers of 22 and 50 kHz USVs and USVs during a visual stimulus (e.g. a potential measure of reinforcement-enhancement) were examined in rats following injection of PCP (2.0 mg/kg) and/or nicotine (0.2 or 0.4 mg/kg) daily for 7 days. PCP was then discontinued and all rats received nicotine (0.2 and 0.4 mg/kg) and PCP (2.0 mg/kg) on three challenge days. PCP acutely decreased 50 kHz vocalizations, whereas repeated nicotine potentiated rates of vocalizations, with similar patterns during light presentations. Rats in the PCP and nicotine combination groups made more 50 kHz vocalizations compared with rats in the control groups on challenge days. We conclude that PCP may produce a reward deficit, which is shown by decreased 50 kHz USVs, and behaviors post-PCP exposure may best model the comorbidity between schizophrenia and nicotine.
Introduction
Tobacco use is a serious health problem, with ∼ 400 000 people dying annually in the USA from nicotine (NIC)related concerns (Center for Disease Control, 2014) . Tobacco addiction is an especially severe problem within the population of schizophrenic patients; between 50 and 90% of the schizophrenic population uses tobacco in some form, compared with 20-35% of the general population in the USA (Kumari and Postma, 2005) . This increased dependence on tobacco products leads to damaging health problems in this subpopulation, shown by the increased incidence of cardiovascular and respiratory diseases, as well as by a smoking-related mortality rate that is two to three times higher than that in the general population (Buda et al., 1988; Mortensen and Juel, 1990; Hennekens et al., 2005; Saha et al., 2007) .
Although a number of hypotheses have been proposed as to the factors involved in the comorbidity of tobacco use and schizophrenia, there is currently no consensus in the field. A number of studies have suggested a role of reward in the comorbidity between tobacco use and schizophrenia. For example, anhedonia, which is defined as the lack of an ability to gain pleasure or reward, is a common symptom seen in many schizophrenic patients (Gopalaswamy and Morgan, 1986) . Patients with schizophrenia rank smoking above other natural rewards, more so than non mentally-ill individuals (Smith et al., 2002) . These findings implicate an alteration in reward-related behavior in patients with schizophrenia who smoke, yet there is a patent lack of preclinical research on the reward system and reinforcement efficacy in this comorbidity.
This study aimed to determine how reward and affective states are affected by NIC and phencyclidine (PCP), which was used to model certain symptoms of schizophrenia in rats. Ultrasonic vocalizations (USVs) have recently come to attention as potential measures of the emotional and motivational states of rats, including reward (Panksepp and Burgdorf, 2000; Mu et al., 2009; Browning et al., 2011; Maier et al., 2012) . Specifically, 50 kHz vocalizations are typically emitted in reinforcerassociated contexts (Sales, 1972; White et al., 1990; Knutson et al., 1998; Panksepp and Burgdorf, 2000; Brunelli et al., 2006; Schwarting et al., 2007) , whereas 22 kHz vocalizations are generally associated with aversive situations (Francis, 1977; Tonoue et al., 1986; Jelen et al., 2003; Wöhr et al., 2005; Mead et al., 2008; Sun et al., 2010) . Wright et al. (2010) further categorized vocalizations into subcategories that may lead to better classification of emotional and motivational states. To date, the few studies examining PCP have shown that PCP decreased tickling-induced 50 kHz vocalizations and increased 22 kHz vocalizations Boulay et al., 2013) , behavior suggestive of a more negative affective state after PCP exposure, which may be considered a model of anhedonia seen in schizophrenics.
Although there have been relatively few studies on the impact of an animal model of schizophrenia on USVs, there have been even fewer on NIC and none on the interaction of phencyclidine and NIC. Data so far have suggested that repeated NIC potentiated USVs, whereas acute administration produced no effect (Simola et al., 2012 (Simola et al., , 2014 . However, these studies only examined the general reinforcing and potentially aversive effects of NIC. Nicotine has been suggested to have dualreinforcement properties, with a relatively weak primary reinforcing effect and a reinforcement-enhancing property, both of which contribute to tobacco addiction ). The reinforcement-enhancement effect is typically defined as enhancement of the reinforcing effects of other nondrug stimuli by NIC and has been reliably demonstrated in preclinical models (Raiff and Dallery, 2006 Thiel et al., 2009; Barrett and Odum, 2011) . Although the dual-reinforcement model has been examined in healthy patients, there is no research comparing these two properties of NIC in a preclinical model of schizophrenia symptoms, nor any research examining these properties utilizing USVs.
The purpose of this study was three-fold. First, PCP produces differential behavioral responses after acute and chronic exposure, as well as after discontinuation (Nabeshima et al., 1983; Jentsch and Roth, 1999; Mouri et al., 2007) , and these three frequently used treatment regimens have not been compared using the USV paradigm to evaluate their effects on positive and negative affective states. By evaluating the effects of acute and chronic treatment, in addition to the postcessation effect of PCP treatment, this study aimed to illuminate which treatment regimen may be most sensitive to the effects of NIC. Second, as discussed, this study aimed to show how NIC interacts with the PCP treatment regimens, as well as to detail the acute and chronic effects of NIC in the USV paradigm. Finally, this study proposed a putative model of comparing the primary reinforcing and reinforcement-enhancement effects of NIC by examining USVs before and during a brief visual stimulus. This visual stimulus is mildly reinforcing to a rat (Berlyne and Koenig, 1965; Glow and Russell, 1975) and is frequently used in testing the reinforcement-enhancing effect (Donny et al., 2003; Palmatier et al., 2006; Chaudhri et al., 2007; Barrett and Bevins, 2012) . On the basis of these findings, reinforcement-enhancement was hypothesized to be seen as an increase in USVs during a light presentation. Overall, examining the individual effects of NIC and PCP, the interactions between these compounds, and how a visual stimulus may affect USVs after drug treatment could preclinically delineate factors involved in the schizophrenia and NIC addiction comorbidity.
Methods

Subjects
Forty-six adult male Sprague-Dawley rats (275-299 g upon arrival; Harlan, Indianapolis, Indiana, USA) were used in the final analysis. Two animals were excluded because of extremely high levels of 22 kHz vocalizations during an early session (e.g. over 500 vocalizations in 5 min), suggesting an acute stressor or pain that was not present in other animals. They were individually housed in clear rectangular polycarbonate tubs (48.3 cm × 26.7 cm × 20.3 cm) under 12-h light/dark conditions to avoid potential isolation-induced vocalizations. Experiments were conducted during the light cycle (light on between 06:00 and 18:00 h). Room temperature was maintained at 22 1°C with a relative humidity of 45-60%. Water was continuously available and food was freely available. The animals were allowed 5 days of habituation to the animal facility before being used in the experiments, during which every rat was handled for 5 min by each experimenter. All procedures were approved by the Institutional Animal Care and Use Committee at the University of Nebraska-Lincoln.
Apparatus
Eight identical two-way shuttle boxes custom designed and manufactured by Med Associates (St. Albans, Vermont, USA) were used. Each box was housed in a ventilated, sound-insulated isolation cubicle (96.52 cm W × 35.56 cm D × 63.5 cm H). Each box was 64 cm long, 30 cm high (from grid floor), and 24 cm wide, and divided into two equal-sized compartments by a white PVC partition with an arch-style doorway (15 cm high × 9 cm wide at base). An aluminum hurdle (4 cm high) was placed in between the two compartments. The grid floor consisted of 40 stainless steel rods of 0.48 cm diameter, spaced 1.6 cm apart center to center. Two cue lights (28 V) were mounted at the top of each compartment, and a house light (50 V) was located at the top of each soundproof chamber. All testing procedures were controlled by Med Associates programs running on a computer. Background noise (∼74 dB) was provided by a ventilation fan affixed at the top corner of each isolation cubicle.
In each two-compartment chamber, a USV microphone (P48 Avisoft Bioacoustics/Emkay Microphone; Avisoft Bioacoustics, Berlin, Germany) was mounted on the ceiling. The microphone was connected to a computer through an E-MU 0404 USB audio device (Awisoft Bioacoustics). Acoustic data were displayed in real time by the Avisoft RECORDER, a multichannel triggering hard-disk recording software (version 3.4; Avisoft Bioacoustics), and were recorded at a sampling rate of 192 kHz in the 16-bit format (version 4.51; Avisoft Bioacoustics). Recording of vocalizations was started exactly 5 s before the Med Associates program and was manually synchronized before analysis.
Spectrograms were generated from the sound files using RavenPro 1.5 (Cornell Laboratory of Ornithology, Ithaca New York, USA: 512 sample Fourier transformation with a Hann window function; filter bandwidth 135 Hz; frequency resolution 93.8 Hz; grid time resolution 2.13 ms). Two trained scorers hand-counted both 50 and 22 kHz vocalizations, with the criteria that 22 kHz vocalizations occurred in the range between 20 and 25 kHz and 50 kHz vocalizations occurred between 30 and 95 kHz. Scorers classified the 50 kHz vocalizations into 14 different categories (complex, composite, downward ramp, upward ramp, flat-trill combination, flat, short, inverted U, multistep, trill, trill with jumps, step down, step up, and split) on the basis of the parameters set forth by Wright et al. (2010) . The inter-rater reliability was assessed using a subset of 700 vocalizations, with 94% of calls receiving the same classification between scorers.
Procedure
Each rat was habituated to the chambers for 30 min per day for 2 days. During these habituation sessions, the rats were placed in the chambers with a house light on. The rats were preinjected with NIC in their home cage 2 h after each habituation session, to potentially attenuate an initial aversion to NIC (Bevins et al., 2001) . After habituation, the rats were randomly assigned to six groups on the basis of the drugs administered before each drugtesting session: SAL-SAL, SAL-NIC 0.2 mg/kg, SAL-NIC 0.4 mg/kg, PCP-SAL, PCP-NIC 0.2 mg/kg, and PCP-NIC 0.4 mg/kg. For a total of seven daily drug-testing sessions, the rats were injected with the drug (SAL, 2.0 mg/kg PCP, and the corresponding NIC dose) and then placed in the chambers for 30 min. USVs were recorded during the entire 30-min session. During this time, lights were presented on a variable time 95 s schedule, with an average of 19 presentations per session. Light presentations involved brief onset of the cue lights (5 s) and termination of the house light for 5 s. The exact time period for which the cue light was presented was recorded. Vocalizations were recorded over all 7 days of testing.
After the drug testing, the rats were not exposed to PCP or NIC for 7 days. They were then placed in the vocalization recording chambers for a series of challenge days. During these challenge days, all rats, regardless of their previous drug treatment history, were tested under the same drug condition. On the first challenge day, they received NIC (0.2 mg/kg). This was followed by NIC (0.4 mg/kg) and PCP (2.0 mg/kg) challenge days. The challenge days were presented in this order so as to keep constant the number of days of PCP nonexposure across animals.
Drugs
(− )Nicotine tartrate salt (Sigma, St. Louis, Missouri, USA) was dissolved in 0.9% saline (SAL) and adjusted to a pH of 7.0 0.2 with a dilute NaOH solution. The high dose (0.4 mg/kg) was chosen on the basis of previous research showing reinforcement-enhancement at that dose ) and, because of the potential of a ceiling effect, a further lower dose (0.2 mg/kg) was chosen on the basis of pilot data. PCP hydrochloride (a gift from NIDA Chemical Synthesis and Drug Supply Program) was obtained by mixing the drug with 0.9% SAL. SAL and PCP (2.0 mg/kg) were administered subcutaneously 10 min before placement in the chamber and NIC (0.2 or 0.4 mg/kg) was administered subcutaneously 5 min before chamber placement. All doses are expressed as base. The dose of PCP was chosen on the basis of unpublished pilot data suggesting that this dose, in combination with NIC doses, would affect USVs. This dose has also been used to model symptoms of schizophrenia in a similar regimen (Jentsch et al., 1997; Abdul-Monim et al., 2003 .
Statistical analyses
To determine whether the vocalizations differed between the six groups and seven testing sessions, multiple analyses of variance (ANOVAs) were carried out. Factorial two-way ANOVAs targeted at the hypotheses were carried out to examine 50 and 22 kHz vocalizations. In addition, two one-way ANOVAs were used to determine differences in the 50 kHz category types independently for the testing sessions, with group as the independent variable and the number of vocalizations in each category as the dependent variable. One-way ANOVAs were carried out to examine the differences on the challenge days, with group as the independent variable and the number of 50 kHz vocalizations as the dependent variable. Fisher's least significant difference (LSD) tests were used as post-hoc tests to attempt to protect from false positives, with the minimum mean difference (mmd) reported. The significance level was set at 5% and was two-tailed.
Results
Total 50 kHz
Using targeted one-way ANOVAs to examine the hypotheses, we first assessed how PCP would affect vocalizations over days (Fig. 1) . On day 1, we found a marginally significant difference between PCP-SAL and SAL-SAL groups [F(1,14) = 4.509, P = 0.053]. PCP did not change 50 kHz vocalizations on days 2 through 7 (P ≥ 0.1). Fisher's LSD tests showed that the PCP-SAL group had lower vocalizations on the first day compared with the SAL group (P < 0.02).
A one-way ANOVA comparing NIC groups with the SAL group was carried out to determine the effects of NIC on 50 kHz vocalizations (Fig. 2 ). There was a significant difference between groups on day 7 [F(2,23) = 4.99, P < 0.05], but there were no significant differences on days 1 through 6 (P ≥ 0.2). Fisher's LSD tests showed that the low-dose NIC group was significantly different from the SAL group (P < 0.01). These results suggest that, after repeated exposure, low-dose NIC led to increased vocalizations compared with SAL.
Finally, ANOVAs were carried out to compare the interaction between PCP and NIC. There were no significant differences between the SAL-NIC 0.2 and PCP-NIC 0.2 groups on any day (P ≥ 0.3). There were also no significant differences between the SAL-NIC 0.4 and PCP-NIC 0.4 groups (P ≥ 0.2). These results suggest that the combination of NIC and PCP did not affect vocalization rates after acute and repeated treatment.
kHz during light
On examining 50 kHz USVs during light presentations, we found similar results (Fig. 3 ). There was a significant difference on day 1 [F(1,14) = 5.02, P < 0.05] and a marginally significant difference on day 2 [F(1,14) = 4.23, P = 0.06]. There were no significant differences on days 3 through 7 (P ≥ 0.4). Fisher's LSD tests showed that the PCP-SAL groups had lower 50 kHz USVs on days 1 and 2 (P ≤ 0.02). These results suggest that PCP decreased 50 kHz vocalizations during light presentations on the first day and marginally decreased vocalizations on day 2.
On comparing 50 kHz USVs emitted during the light presentations for NIC, we again found that there was a significant main effect of group [ Fig. 4 ; F(2,23) = 5.35, P < 0.05]. LSD tests showed that there was a significant difference for both the low-dose group (P < 0.05) and the high-dose group (P < 0.05) compared with the SAL group. There were no significant differences between groups on days 1 through 6 (P ≥ 0.2). These results show that both the low-dose and the high-dose NIC groups had higher levels of 50 kHz USVs during light presentations on the final day of testing.
Finally, interactions between NIC and PCP were tested. No significant differences on any day were found when comparing SAL-NIC 0.2 with PCP-NIC 0.2 (P ≥ 0.09) or SAL-NIC 0.4 with PCP-NIC 0.4 (P ≥ 0.2). These results suggest that the combination of NIC and PCP did not affect vocalization rates after acute and repeated treatment during the light stimulus.
kHz categories
In addition to total vocalizations, the 50 kHz USVs were separated into 13 different categories. Separate one-way ANOVAs were carried out to assess the differences in the types of 50 kHz calls emitted on the 7 days of treatment ( Fig. 5 ). On the first day, the groups showed significant differences in composite vocalizations [F(5,39) = 2.87, P < 0.05], as well as in multistep vocalizations [F(5,39) = 3.75, P < 0.01]. Pairwise comparisons (LSDmmd = 19.98) showed that the SAL-SAL group had more composite vocalizations than all other groups (P < 0.02) and more multistep calls than all other groups (LSDmmd = 18.62, P < 0.02). In addition, there was a trend toward a difference in upward ramp vocalizations between the groups [F(5,39) = 2.45, P = 0.05]. Pairwise comparisons (LSDmmd = 43.72) revealed that the SAL-SAL group produced more upward ramp vocalizations than the SAL-NIC 0.4, PCP-NIC 0.2, and PCP-NIC 0.4 groups ( Fig. 5 ; P < 0.02).
There were no significant differences in the types of calls emitted by the groups on days 2 through 6 (P ≥ 0.08). On day 7, there was a significant difference in the multistep calls between the six groups [F(5,39) = 2.67, P < 0.05]. Pairwise comparisons (LSDmmd = 7.73) showed that the PCP-NIC 0.4 group had significantly fewer multistep vocalizations than the SAL-SAL and SAL-NIC 0.4 groups (P ≤ 0.05). In addition, on day 3, there was a significant difference in the number of uncategorized calls between the six groups [F(5,39) = 2.71, P < 0.05]. Pairwise comparisons (LSDmmd = 6.17) showed that the SAL-NIC 0.4 group had significantly more uncategorized calls than all of the other treatment groups (P ≤ 0.05). These calls looked similar to 50 kHz vocalizations but appeared in the 22 kHz range (Fig. 6 ).
kHz vocalizations
There were no significant effects of any of the measures on total 22 kHz USVs (Ps ≥ 0.3) or 22 kHz USVs during light stimuli (P ≥ 0.2). Only 19 total 22 kHz USVs were emitted on all drug-testing days and only one vocalization was emitted during the light stimuli over all testing days.
Challenge days
The three challenge days showed significant differences in the number of 50 kHz calls. On the first challenge day, when rats were administered a low dose of NIC (0.2 mg/kg), there was a significant difference in the number of calls between the six groups, [ Fig. 7 ; F(5,33) = 6.01, P < 0.001]. Pairwise comparisons (LSDmmd = 352.19) indicated that the SAL-NIC 0.4 group emitted significantly more vocalizations than all other groups (P ≤ 0.005) except the SAL-NIC 0.2 group (P = 0.051). In addition, the SAL-NIC 0.2 group produced significantly more vocalizations than the SAL-SAL group (P = 0.01).
On the second challenge day, when rats were administered a high dose of NIC (0.4 mg/kg), there was a significant difference in the number of calls between the six groups [ Fig. 8 ; F(5,33) = 3.25, P < 0.05]. Pairwise comparisons (LSDmmd = 229.16) indicated that the SAL-NIC 0.4 group emitted significantly more vocalizations than all other groups (P < 0.05).
On the third challenge day, when rats were administered PCP, there was a significant difference in the number of calls between the six groups [ Fig. 5 ; F(5,33) = 8.35, P < 0.02]. Pairwise comparisons (LSDmmd = 503.99) showed that the PCP-NIC 0.2 and PCP-NIC 0.4 groups were not significantly different (P = 0.06), and these two groups produced significantly more vocalizations than the other groups (P < 0.001; Fig. 9 ).
Discussion
First, we found that NIC and PCP altered total vocalizations in an opposing manner: PCP, after acute treatment, seemingly decreased total 50 kHz vocalizations, whereas NIC treatment led to higher total vocalizations compared with control groups, but only after repeated exposures. Similar findings were obtained for the 50 kHz vocalizations during the visual stimulus presentations. There were no differences in 22 kHz vocalizations. When considering categories of vocalizations, specific subtypes were differentially affected by NIC and PCP treatment. Finally, no consistent interactions were seen during acute and chronic PCP treatment, but only animals that had On examining overall vocalizations elicited throughout the session, acute PCP exposure appeared to produce a more negative affective state, as shown by a decrease in 50 kHz vocalizations. This finding is analogous to the findings of a recent study showing that PCP attenuated tickling-induced 50 kHz vocalizations (Boulay et al., 2013) . Although this experiment had a number of methodological differences compared with our experiment (i.e. different ages of rats, tickling-induced vocalizations, different dosage), the similarities in the findings suggest that the attenuation of 50 kHz USVs by PCP is a relatively robust effect. Boulay et al. (2013) suggested that this decrease may model anhedonia (a negative symptom of schizophrenia) and the results of the present study support this idea. In contrast to research on 'aversive' vocalizations ), PCP did not increase 22 kHz vocalizations in this paradigm, but only altered 50 kHz USVs, suggesting that decreases in 50 kHz vocalizations might be a better measure to examine reinforcement differences.
Contrary to the effects of PCP on 50 kHz vocalizations, the group receiving the high dose of NIC had higher levels of vocalizations associated with positive affective states in comparison with control groups, but this effect was only seen after repeated NIC exposure. In previous studies, acute NIC did not produce significant changes in the total number of 50 kHz USVs (Simola et al., 2012) but repeated NIC treatment led to increased vocalizations over days (Simola et al., 2014) . Our findings support these previous findings in terms of acute and chronic effects, Differences between groups on the first drug session in subtypes of 50 kHz vocalizations (mean SEM). SAL-SAL had higher composite and multistep vocalizations than all other groups, and groups that had previously received high-dose nicotine (0.4 mg/kg) had lower upward ramp vocalizations. # P = 0.50; *P < 0.05. n = 7 or 8/group. NIC, nicotine; PCP, phencyclidine; SAL, saline.
with NIC producing no significant effect on the first day but causing increased numbers of USVs in comparison with SAL on the final day of treatment. Similarities between these results suggest that repeated exposure may be necessary to see the reinforcing activity of NIC in the USV paradigm. Repeated NIC exposure is integral in other paradigms and appears to be integral to development of reinforcement-enhancement effects of NIC (Raiff and Dallery, 2006; Palmatier et al., 2007; Barrett and Odum, 2011) As alterations in rates of USVs may potentially be used to elucidate mechanisms behind drug dependence, such as sensitization and tolerance (Taracha et al., 2014) , exploring the mechanisms behind this repeated effect of NIC and its relationship to behavioral and neurobiological factors involved in drug dependence is vital to further detail the importance and validity of examining USVs for drug addiction measures.
Vocalizations during light presentations were examined, in addition to overall vocalizations, to determine if USVs might be sensitive enough to illuminate differences in the reinforcement-enhancement effects of drugs. Reinforcement-enhancement was hypothesized to be seen as an increase in USVs during a light presentation. However, overall vocalizations did not seem to change significantly during light presentations (not shown) and temporal patterns were fundamentally similar to those seen during no light presentation, although the effects of PCP lasted longer when examining vocalizations during light. It is possible that this paradigm is not sensitive enough to fully detail the reinforcement-enhancement effect of drugs. It is also possible that the reinforcing value of the stimuli might not be sufficient to detect differences. The noncontingent nature of the stimuli could potentially reduce the reinforcing value of the visual stimulus or the length of the visual stimulus may have been too short, as others have used significantly longer stimuli (Caggiula et al., 2002; Donny et al., 2003; Palmatier et al., 2006; Chaudhri et al., 2007; Barrett and Bevins, 2012) . Future research to determine if the reinforcement-enhancement effects of NIC can be seen in this paradigm is warranted, as USVs do not rely on locomotor activity, which can significantly affect operant behavior typically used to study reinforcementenhancement.
We also found that different subtypes of 50 kHz vocalizations were differentially affected by acute treatment with both PCP and NIC. Both PCP and NIC significantly decreased composite and multistep subtypes of vocalizations after acute treatment. Rats that had previously received NIC had fewer upward ramp vocalizations, yet the number of total vocalizations was not significantly different. All of the subtypes affected by both NIC and PCP exposure were frequency-modulated; there were no differences in either total or light-paired flat vocalizations. In addition, NIC did not alter trill vocalizations, in agreement with the findings of Simola et al. (2014) . The importance of subtypes is not currently known, but different categories of vocalizations have been hypothesized to have different behavioral significances (Wright et al., 2010) . As 50 kHz calls can occur under potentially aversive situations (see Wohr et al., 2008 for discussion), examination of specific subcategories of 50 kHz vocalizations might be better suited to examine reward and reinforcement. For example, frequency-modulated calls such as trills are associated with appetitive stimuli (Burgdorf and Panksepp, 2006; Burgdorf et al., 2007; Wohr et al., 2008; Ahrens et al., 2013) , whereas flat vocalizations are observed under nonappetitive situations such as during short periods of isolation (Wohr et al., 2008; Stevenson et al., 2009 ).
Vocalization analysis not only uncovered differences in established 50 kHz subtypes but additional vocalizations resembling 50 kHz subtypes were seen in the range associated with 22 kHz vocalizations (Fig. 7) . These vocalizations were placed in the uncategorized vocalization subtype, and a potentiation of total vocalizations in this category was seen in the SAL-NIC 0.4 group. Given that differences in 50 kHz USVs may have different behavioral implications, it is possible that subtypes of 22 kHz vocalizations might also be associated with different features. Calls of 22 kHz have been examined for their temporal nature (Brudzynski et al., 1993) and frequency of modulation (see Litvin et al., 2007 , Vivian and Miczek, 1993a , 1993b , and considerably short 22 kHz vocalizations have been found during drug treatment (Barker et al., 2010) . To the authors' knowledge, USVs in the 22 kHz range resembling the vocalizations found in this experiment have not been identified previously. Further replication of this USV subtype and experimentation involving devocalization surgery is necessary; however, these results are intriguing, especially given the differences seen in these vocalizations after NIC treatment.
The previous discussion has focused on acute and chronic exposure to PCP and NIC. In these two treatment regimens, no interaction was found between NIC and PCP. Interactions were, however, seen on challenge days. On the NIC challenge days, only a basic sensitization effect was seen; previous exposure to NIC (either with or without PCP on board) led to increased 50 kHz vocalizations. However, the most interesting findings occurred on the PCP challenge day. Rats that had received both NIC and PCP had higher levels of vocalizations on the PCP challenge day; this was significantly different from that in rats that had only received PCP and from that in groups that had only received NIC.
The finding that an interaction between PCP and NIC is only seen on challenge days is consistent with findings on the differential effects of PCP treatment regimens on schizophrenia-related behaviors. Acute exposure, chronic exposure, and cessation of PCP treatment consistently yield behavioral differences in a number of paradigms, specifically in relation to negative symptoms (for review, see Neill et al., 2013) . Here, we see that the interaction between the two drugs is only seen after PCP treatment has been discontinued. It is possible that rodents in this animal model of negative symptoms of schizophrenia might be more sensitive to the reinforcing effects of NIC after cessation of PCP treatment, given the increase in 50 kHz USVs seen only in the groups with the pairing.
Thus, this discontinuation model may be better suited to modeling the negative symptoms of schizophrenia (Ellenbroek and Cools, 2000) . Therefore, it may be possible that schizophrenic patients with a higher preponderance of negative symptoms may be more sensitive to the reinforcing effects of NIC, which could increase NIC use. Although some human research supports this suggestion, such as the study by Ahnallen et al. (2012) , which shows that the severity of anhedonia is correlated with the severity of NIC dependence, it is still speculative and there is a clear need for more research on this idea. Another possibility is that effects on the PCP challenge day may be influenced by the conditioning between PCP and NIC. The interoceptive state of PCP could act as a cue to 'predict' NIC, with the lack of NIC or previous conditioning to the PCP/NIC combination influencing USVs. Further research on the effects of conditioning is needed to elucidate the mechanisms behind the challenge day difference.
Overall, this experiment suggests that both PCP and NIC alter 50 kHz vocalizations in different ways. PCP acutely decreased 50 kHz vocalizations, whereas repeated exposure to NIC led to higher levels of 50 kHz vocalizations. Specific frequency-modulated vocalizations were lessened by NIC and PCP. This is the first study to report differences in subtypes of vocalizations on PCP exposure. Given the complexities of the PCP model of schizophrenia symptoms, examination of different call profiles of animals in this model is warranted, and further examination of the interaction of antipsychotics with this effect would be illuminating. Vocalization subtypes resembling those seen in the 50 kHz categories were also observed in the 22 kHz range. Given that these vocalizations increased after NIC treatment, future research on the potential mechanisms and behavioral significance of these vocalizations is necessary. Finally, this study lends credence to the idea that examining behaviors after discontinuation of PCP may better model discrepancies in reward and reinforcement seen in patients with schizophrenia that might not be uncovered during acute and chronic treatment.
